Research Grade Zinlirvimab

Catalog No.

DVV03103

Expression system

Mammalian Cells

Species reactivity

Human immunodeficiency virus 1 (HIV-1)

Host species

Human

Isotype

IgG1, lambda2

Clonality

Monoclonal

Target

gp120/Glycoprotein 120

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q03805

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

GS 2872, GS-2872, GS2872, CAS: 2417213-75-1

Clone ID

Zinlirvimab

Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab., PMID:40176256

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023., PMID:39363782

Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy., PMID:39298557

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study., PMID:38307098

Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV., PMID:37265259

Document Download

Research Grade Zinlirvimab.pdf